Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options. [electronic resource]
Producer: 19960725Description: s44-5 p. digitalISSN:- 0887-6924
No physical items for this record
Publication Type: Editorial
There are no comments on this title.
Log in to your account to post a comment.